'Next-generation therapeutic antibody revenues to reach $2.3bn in 2015' reports Visiongain
Visiongain predicts that the antibody therapeutics sector will be revitalised by the approval of next-generation products this decade. Overall next-generation therapeutic antibody revenues will reach $2.3bn in 2015.
- (1888PressRelease) November 11, 2011 - Visiongain's report identifies seven new classes of antibody products that will have marketed products by 2016. Engineered monoclonal antibodies with improved glycosylation and enhanced effector functions are already reaching the market. So are antibody-drug conjugates (ADCs) and bispecific antibodies, sectors that have gained their first approvals in the past two years. Dynamic R&D pipelines underpin these classes of antibodies. They will be joined in the next five years by third-generation antibody fragments, alternative binding proteins and new-generation recombinant polyclonal antibodies. Biosimilar antibodies will also enter the established markets as regulatory authorities clear an approval pathway for them.
Dr James Evans, pharmaceutical industry analyst, said: "The antibodies sector has never stood still, but right now it's on the verge of several potentially significant breakthroughs. ADCs, bispecifics and other technologies will increase antibody potency to new levels. New miniaturised fragments may be able to hit clinical targets inaccessible to full-size existing products. Alternative binding proteins and recombinant polyclonal antibodies could challenge the existing monoclonal immunoglobulin paradigm. Also, biosimilar antibodies are coming, and will be important in the developed national markets, where demand for them is high."
The overall antibody-based drug market will grow steadily this decade, the report shows. The next-generation share of therapeutic antibody revenues will increase as those newer products outstrip the existing market leaders for revenue growth. With higher potency, broader targeting, more-convenient delivery systems, and lower costs among the benefits offered by next-generation antibody products, their commercial impact will be significant. This new study adds to visiongain's range of analytical reports covering fast-developing markets in the pharmaceutical industry.
To view sample pages please visit http://www.visiongain.com/Report/712/Next-Generation-Antibody-Therapies-Pipeline-and-Market-2011-2021
For an exec summary please contact Sara Peerun
Email : sara.peerun ( @ ) visiongainglobal dot com
Tel: +44 207 3366100
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun ( @ ) visiongainglobal dot com or call her on +44 (0) 207 336 6100
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam